Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | MPO | P05164 | 4/20 | 0.71 |
| ▸ | HTR1D | P28221 | 4/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | SPR | P35270 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | IDO1 | P14902 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22953701 | 0.92 | MPO (0.72) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL453066 | 0.91 | TRPV1 (0.67) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL15920450 | 0.90 | HTR2C (0.74) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL25076884 | 0.89 | TRPV1 (0.69) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL23633204 | 0.89 | TRPV1 (0.69) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL25076883 | 0.89 | TRPV1 (0.69) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL23633206 | 0.89 | TRPV1 (0.69) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL25076891 | 0.89 | TRPV1 (0.69) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL14907374 | 0.89 | TRPV1 (0.69) | HTR2CKDM4ECYP2D6MEN1KMT2A | |
| SCHEMBL23630278 | 0.89 | TRPV1 (0.69) | HTR2CKDM4ECYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024008341-A1 | SEROTONIN ANALOGUES FOR USE IN TREATING METALLOPTOSIS-ASSOCIATED DISORDERS | INSTITUT CURIE (FR) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023021112-A1 | NOVEL SEROTONIN DERIVATIVES AND THEIR USES FOR TREATING IRON-ASSOCIATED DISORDERS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2023-02-23 | — | — | WO | disclosed |
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-29 | — | — | US | disclosed |
| US-9073851-B2 | Compositions and methods for treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013063492-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | HDGF, HCCS, CCNC | HTR2C 380/4885KDM4E 2945/4885CYP2D6 4819/4885 |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | HDGF, HCCS, CCNC | HTR2C 380/4885KDM4E 2945/4885CYP2D6 4819/4885 |
| US-20240335418-A1 | SAFER PSYCHOACTIVE COMPOSITIONS | HTR6, HTR4, CNR1 | HTR2C 11/4885KDM4E 3854/4885CYP2D6 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.